CASI Pharmaceuticals, Inc.

Transcription

1 CASI Pharmaceuticals, Inc. Your Strategic Drug Development Partner in China NASDAQ: CASI

2 Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance, strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forwardlooking statements speak only as of the date they are made, and no duty to update forwardlooking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors. Such factors, among others, could have a material adverse effect upon our business, results of operations and financial condition. Additional information about the factors and risks that could affect our business, financial condition and results of operations, are contained in our filings with the U.S. Securities and Exchange Commission ("SEC"), which are available at Slide 2

3 Who We Are CASI Pharmaceuticals, Inc. is a US-headquartered, NASDAQ-listed biopharmaceutical company with a dedicated regional focus and strong presence in China Focused on the acquisition, development, and commercialization of oncology assets for China and other global markets Core competency is to conduct high quality global clinical trials in China for drug candidates from Western countries with efficiency and speed under international standards Management team has practical drug development experience both in the US and China, with proven track record of successful Chinese FDA filings and approvals Financially strong with backing from IDG-Accel and Kleiner Perkins Caufield & Byers as our shareholders Our unique US/China approach positions us to help our partners strategically advance their clinical assets cost-effectively Slide 3

4 What We Can Do For You Launch your product in China up to three years sooner than a more traditional development approach Have your global Phase 3 programs completed faster Accelerate your Phase 1 and 2 clinical candidates and reach proof-ofconcept inflection points or expand into additional indications Clinical data generated in China can be utilized for your global development and regulatory filings in the US We will cover development costs in China In return we seek exclusive rights in China through in-licensing/codevelopment arrangements Slide 4

5 Why China? China s pharmaceutical spending is expected to grow 14-17% per annum over the next 5 years, reaching $170 billion and becoming the 2 nd largest market in the world by Now is the time to gain a foothold in the Chinese market. Slide 5

6 Why China Oncology? China s oncology market is growing at a rapid rate due to an increase in cancer incidence. It will likely become the world s largest market in the next 5-10 years. Slide 6

7 A Seasoned, Bi-Cultural Board and Senior Management Team BOARD OF DIRECTORS Dr. Wei-Wu He, Chairman CEO and Chairman of OriGene Technologies, Inc.; healthcare venture partner of IDG-Accel, a major venture capital firm in Asia; founder and General Partner of Emerging Technology Partners, LLC, a life sciences focused venture fund. Dr. He is a seasoned leader in the biotechnology industry with solid financing and business acumen in the U.S. and China. Dr. Tak W. Mak, Chief Scientific Advisor Director of the Campbell Family Institute for Breast Cancer Research at the Princess Margaret Hospital and a University Professor at University of Toronto; Former VP Research at Amgen; Best known as leading scientist to first clone the genes of the human T cell antigen receptor. Dr. Mak s current and past groundbreaking research has earned him numerous awards. James Huang Managing partner of Kleiner Perkins Caufield & Byers China, with 20+ years experience in the biopharmaceutical industry, including financing and business development. Mr. Huang has deep experience, numerous contacts and extensive industry knowledge in the U.S. and China. OFFICERS Dr. Ken K. Ren, CEO Formerly an entrepreneur and seasoned executive with healthcare companies, including serving as the President of Accelovance (China) where Dr. Ren oversaw multiple global clinical trials including regulatory and development activities in China for international companies such as J&J, Eli Lilly, Novartis and Amgen. Dr. Ren started his career as a research scientist, and holds a MD from the Shandong University School of Medicine and a PhD from the State University of New York at Buffalo. Cynthia W. Hu, COO, General Counsel & Secretary Experienced biotech executive in corporate development, financing, legal and operations. Ms. Hu started her career as a corporate attorney specializing in corporate finance, securities, M&A, and public company governance. Sara Capitelli, VP Finance, Principal Accounting Officer Experienced in public company accounting and finance. Former experience includes serving as senior manager at Ernst & Young providing accounting and audit services to clients in a variety of industries. Dr. Y. Alexander Wu CEO and co-founder, Crown Biosciences, Inc., with 20+ years experience in the biopharmaceutical industry in the oncology sector, and has held senior positions in research, business development, and corporate strategy. Dr. Wu manages his business in the U.S. and China and has extensive industry knowledge in both countries. Franklin C. Salisbury, Jr., M.Div., J.D. President of the National Foundation for Cancer Research (NFCR) since 1997, leading NFCR to expand its cancer research program from basic cancer research to translational and clinical research. Mr. Salisbury also serves on the Board for the Asian Fund for Cancer Research based in Hong Kong, China, NFCR s sister foundation. Slide 7